Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Compared with Pexidartinib of Daiichi Sankyo, Abbisko's Pimicotinib shows better efficacy and safety in the treatment of TGCT.
The data update that we had at ESMO last year clearly shows the potential for vimseltinib to be best-in-class for the treatment of patients with TGCT.